Recently, the State Council issued the "13th Five-Year Plan for the Development of Strategic Emerging Industries of the Country" (hereinafter referred to as "Planning"), and made plans for the development goals, key tasks, and policy measures of China's strategic emerging industries during the 13th Five-Year Plan period. Full deployment arrangements.
Among them, the planning focuses on “accelerating the pace of innovation and development of bio-industry and cultivating new bio-environmentâ€, and proposes to build a new bio-pharmaceutical system, upgrade the development level of bio-medical engineering, accelerate the development of bio-agricultural industrialization, and promote the scale application of bio-manufacturing. To foster new forms of bioservices and innovative bioenergy development models.
The "Plan" clearly states that by 2020, the scale of the bio-industry will reach 8-10 trillion yuan, forming a group of new biotechnology enterprises and bio-economic clusters with strong international competitiveness. The following are the biomedical-related parts of the module. content:
(1) Constructing a new biomedical system. Accelerate the development of innovative drugs and biological products with major clinical needs, accelerate the promotion of green and intelligent pharmaceutical production technologies, strengthen scientific and efficient supervision and policy support, promote the international development of industries, and accelerate the construction of bio-pharmaceutical powers.
Promote the leapfrogging of the biomedical industry. Accelerate the research and development of technologies such as gene sequencing , cell-scale culture, targeted and long-acting drug release, and green intelligent production to support the high-end development of the industry. Develop new types of antibodies and vaccines, gene therapy, cell therapy and other biological products and preparations, promote chemical drug innovation and high-end formulation development, accelerate the development of distinctive innovative Chinese medicines, and realize the original innovation of major disease prevention and treatment drugs. Support the large-scale development of biosimilar drugs, carry out research and development and production of large-scale patent-expired drugs, accelerate the upgrading of pharmaceutical equipment, improve the level of pharmaceutical automation, digitization and intelligence, further promote the standardization of Chinese medicine products, and promote the integration of industry standard systems with the international standards. Accelerate the pace of internationalization. Develop marine innovative drugs, develop modern marine Chinese medicine products with ethnic characteristics, promote the industrialization of reagent raw materials and intermediates, and form a group of marine biomedical industry clusters.
Innovative biomedical regulatory approach. Establish a more scientific and efficient method for examination and approval of pharmaceuticals, speed up the pilot system for drug listed license holders, speed up the evaluation of the quality and efficacy of generic drugs, and explore pilot programs for the evaluation of clinical trials for medical new technologies. Improve the drug procurement mechanism and comprehensively promote the reform of institutional mechanisms in the fields of pharmaceutical prices and industry supervision.
Door Hardwares,Commercial Door Hardware,Entry Door Hardware,Modern Door Hardware
Zhejiang Tilanco Industry&Trade Group Co., Ltd , https://www.tilancogroup.com